Related Experiment Video

Updated: Apr 15, 2026

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages
06:52

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages

Published on: May 21, 2018

11.4K

[NLRP3 inflammasome and diabetes]

Qilin Liu, Jianwei Li

    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi = Journal of Biomedical Engineering = Shengwu Yixue Gongchengxue Zazhi
    |April 15, 2015
    PubMed

    Insights

    The NLRP3 inflammasome, a key player in metabolic stress, is closely linked to diabetes development. Targeting this pathway offers a promising new strategy for diabetes treatment and improving glucose metabolism.

    Area of Science:

    • Immunology
    • Metabolic Diseases
    • Molecular Biology

    Background:

    • Diabetes mellitus is a global epidemic with severe complications impacting patient quality of life.
    • The NLRP3 inflammasome, involved in metabolic stress response, is implicated in diabetes pathogenesis.
    • Current research focuses on novel therapeutic targets for diabetes prevention and treatment.

    Purpose of the Study:

    • To review the activation and regulation mechanisms of the NLRP3 inflammasome.
    • To elucidate the role of NLRP3 inflammasome in glucose metabolism.
    • To discuss the potential of NLRP3 inflammasome as a therapeutic target for diabetes.

    Main Methods:

    • Literature review of studies on NLRP3 inflammasome activation and regulation.
    • Analysis of research linking NLRP3 inflammasome to metabolic stress and diabetes.
    • Examination of preclinical and clinical data on targeted NLRP3 inflammasome therapies.

    Main Results:

    • NLRP3 inflammasome activation is triggered by metabolic stress signals, leading to IL-1β production.
    • Dysregulation of NLRP3 inflammasome contributes to impaired glucose metabolism and diabetes progression.
    • Inhibition of NLRP3 inflammasome shows potential in ameliorating diabetes-related complications.

    Conclusions:

    • NLRP3 inflammasome is a critical mediator in diabetes development and progression.
    • Targeting NLRP3 inflammasome represents a novel therapeutic avenue for managing diabetes.
    • Further research is warranted to fully explore the therapeutic potential of NLRP3 inflammasome inhibitors in diabetes.

    More Related Videos

    Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells09:04

    Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells

    Published on: May 22, 2014

    21.6K
    Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy08:47

    Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

    Published on: December 7, 2017

    10.4K

    Related Concept Videos

    Insulin: The Receptor and Signaling Pathways01:28

    Insulin: The Receptor and Signaling Pathways

    Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
    6.3K
    PI3K/mTOR/AKT Signaling Pathway01:22

    PI3K/mTOR/AKT Signaling Pathway

    The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
    6.5K
    Glucagon-like Receptor Agonists01:24

    Glucagon-like Receptor Agonists

    Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
    GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
    1.4K